AIM: To evaluate the diagnostic values of serum autoantibodies against matrix metalloproteinase-7 (MMP-7) in patients with esophageal squamous cell carcinoma (ESCC). METHODS: The MMP-7 cDNA was cloned from ESCC tissues, and MMP-7 was expressed and purified from a prokaryotic system. MMP-7 autoantibodies were then measured in sera from 50 patients with primary ESCC and 58 risk-matched controls, using a reverse capture enzyme-linked immunosorbent assay (ELISA) in which autoantibodies to MMP-7 bound to the purified MMP-7 proteins. In addition, MMP-7 autoantibody levels in sera from 38 gastric cancer patients and from control serum samples were also tested. RESULTS: The optimum conditions for recombinant MMP-7 protein expression were determined as 0.04 mmol/L Isopropyl-β-D-Thiogalactopyranoside (IPTG) induction at 37°C for four hours. The levels of serum autoantibodies against MMP-7 were significantly higher in patients with ESCC than in the matched-control samples (OD450 = 1.69 ± 0.08 vs OD450 = 1.55 ± 0.10, P < 0.001). The area under the receiver operating characteristic (ROC) curve was 0.87. The sensitivity and specificity for detection of ESCC were 78.0% and 81.0%, respectively, when the OD450 value was greater than 1.65. Although the levels of autoantibodies against MMP-7 were also significantly higher in patients with gastric cancer compared to control samples (OD450 = 1.62 ± 0.06 vs OD450 = 1.55 ± 0.10, P < 0.001), the diagnostic accuracy was less significant than in ESCC patients. The area of ROC curve was 0.75, whereas the sensitivity and specificity were 60.5% and 71.7%, respectively, when the cut-off value of OD450 was set at 1.60. CONCLUSION: Serum autoantibody levels of MMP-7 may be a good diagnostic biomarker for esophageal squamous cell carcinoma.
AIM: To evaluate the diagnostic values of serum autoantibodies against matrix metalloproteinase-7 (MMP-7) in patients with esophageal squamous cell carcinoma (ESCC). METHODS: The MMP-7 cDNA was cloned from ESCC tissues, and MMP-7 was expressed and purified from a prokaryotic system. MMP-7 autoantibodies were then measured in sera from 50 patients with primary ESCC and 58 risk-matched controls, using a reverse capture enzyme-linked immunosorbent assay (ELISA) in which autoantibodies to MMP-7 bound to the purified MMP-7 proteins. In addition, MMP-7 autoantibody levels in sera from 38 gastric cancerpatients and from control serum samples were also tested. RESULTS: The optimum conditions for recombinant MMP-7 protein expression were determined as 0.04 mmol/L Isopropyl-β-D-Thiogalactopyranoside (IPTG) induction at 37°C for four hours. The levels of serum autoantibodies against MMP-7 were significantly higher in patients with ESCC than in the matched-control samples (OD450 = 1.69 ± 0.08 vs OD450 = 1.55 ± 0.10, P < 0.001). The area under the receiver operating characteristic (ROC) curve was 0.87. The sensitivity and specificity for detection of ESCC were 78.0% and 81.0%, respectively, when the OD450 value was greater than 1.65. Although the levels of autoantibodies against MMP-7 were also significantly higher in patients with gastric cancer compared to control samples (OD450 = 1.62 ± 0.06 vs OD450 = 1.55 ± 0.10, P < 0.001), the diagnostic accuracy was less significant than in ESCC patients. The area of ROC curve was 0.75, whereas the sensitivity and specificity were 60.5% and 71.7%, respectively, when the cut-off value of OD450 was set at 1.60. CONCLUSION: Serum autoantibody levels of MMP-7 may be a good diagnostic biomarker for esophageal squamous cell carcinoma.
Authors: Joan Maurel; Cristina Nadal; Xabier Garcia-Albeniz; Rosa Gallego; Enric Carcereny; Vanesa Almendro; Maribel Mármol; Elena Gallardo; Josep Maria Augé; Raquel Longarón; Alex Martínez-Fernandez; Rafael Molina; Antoni Castells; Pere Gascón Journal: Int J Cancer Date: 2007-09-01 Impact factor: 7.396
Authors: Ho-Sheng Lin; Harvinder S Talwar; Adi L Tarca; Alexei Ionan; Madhumita Chatterjee; Bin Ye; Jerzy Wojciechowski; Saroj Mohapatra; Marc D Basson; George H Yoo; Brian Peshek; Fulvio Lonardo; Chuan-Ju G Pan; Adam J Folbe; Sorin Draghici; Judith Abrams; Michael A Tainsky Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-11 Impact factor: 4.254
Authors: Azizbek Ramankulov; Michael Lein; Manfred Johannsen; Mark Schrader; Kurt Miller; Klaus Jung Journal: Cancer Sci Date: 2008-04-14 Impact factor: 6.716
Authors: Chana Palmer; Xiaobo Duan; Sarah Hawley; Nathalie Scholler; Jason D Thorpe; Rob A Sahota; May Q Wong; Andrew Wray; Lindsay A Bergan; Charles W Drescher; Martin W McIntosh; Patrick O Brown; Brad H Nelson; Nicole Urban Journal: PLoS One Date: 2008-07-09 Impact factor: 3.240
Authors: George Couch; James E Redman; Lorenz Wernisch; Richard Newton; Shalini Malhotra; Sanford M Dawsey; Pierre Lao-Sirieix; Rebecca C Fitzgerald Journal: Cancer Prev Res (Phila) Date: 2016-04-12